The lawyer advising India’s super-specialty hospitals brand Asian Institute of Medical Sciences (AIMS), which received an investment of US$21 million from UK development finance institution CDC Group, said an interesting side of the deal was that it involved two investors with different visions.
The deal was a series B round of fundraising from CDC, following a series A investment of US$15 million in 2014 by existing investor Orbimed, a healthcare fund management company, which will keep its stake in AIMS. “Representing the company and promoters against two investors with different objectives and visions was interesting and unique,” said Akshat Pande, the managing partner of Alpha Partners in New Delhi, who led the team advising AIMS.
“The existing investor had an interest in retaining the terms of their original agreement and the new investor wanted to renegotiate a number of terms to benefit them. Our outlook was to protect the interest of the promoters and the company, and negotiate terms that would not disturb the status quo.”
CDC’s investment will support the company’s five-year expansion into Jharkhand, Bihar and Uttar Pradesh, where it will add 1,000 beds to new and existing multi-specialty sites.
In addition to Pande, the team from Alpha Partners advising AIMS comprised associate partner Kunal Arora and associate Richa Hingle. Trilegal partner Nishant Parikh along with counsel Harsh Jain and corporate associate Sibani Saxena advised CDC. IndusLaw partner Kartik Ganapathy represented Orbimed.
AIMS operates three tertiary care hospitals in Faridabad, Moradabad and Dhanbad, two secondary care hospitals in Delhi and Sambhal, and three health clinics in Faridabad, Palwal and Delhi.